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Abstract Metabolic transformation by the superfamily of
cytochromes P450 (CYPs) plays an important role in the
detoxification of xenobiotics such as drugs, environmental
pollutants, and food additives. Endogenous substrates of
CYPs include fatty acids, sterols, steroids, and bile acids. In-
duction of CYPs via transcriptional activation by substrates
and other xenobiotics is an important adaptive mechanism
that increases the organism’s defense capability against tox-
icity. Numerous in vivo and in vitro data have highlighted
the concept that the molecular mechanism of hepatic drug
induction is linked to endogenous regulatory pathways. In
particular, in vitro data suggest that oxysterols via the liver
X receptor (LXR) inhibit phenobarbital (PB)-mediated in-
duction of CYPs. To study the link between LXR, choles-
terol homeostasis, and drug induction in vivo, we designed
experiments in wild-type, LXR
 

 
-, LXR
 

 
-, and LXR
 

 
/
 

 
-defi-
cient mice. Our data expose differential regulatory patterns
for Cyp2b10 and Cyp3a11 dependent on the expression of
LXR isoforms and on challenge of cholesterol homeostasis
by excess dietary cholesterol.  Our results suggest that,
in the mouse, liver cholesterol status significantly alters
the pattern of expression of Cyp3a11, whereas the absence
of LXR leads to an increase in PB-mediated activation of
Cyp2b10.
 
—Gnerre, C., G. U. Schuster, A. Roth, C. Hand-
schin, L. Johansson, R. Looser, P. Parini, M. Podvinec, K.
Robertsson, J-Å. Gustafsson, and U. A. Meyer.
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The gene superfamily of cytochromes P450 (CYPs) en-
codes a large number of proteins that are typically in-
volved in the metabolism of endogenous, lipid-soluble
compounds. Among others, fatty acids, sterols, steroids,
and bile acids have been identified as endogenous CYP
substrates (1, 2). Furthermore, hepatic CYPs play a promi-
nent role in the metabolic transformation of xenobiotics
such as drugs, environmental pollutants, and food addi-
tives and thus in their detoxification and rapid elimina-
tion from the body (3).
Characteristically, xenobiotic-metabolizing members of
the CYP superfamily are transcriptionally induced upon
exposure to xenobiotics. This phenomenon increases the
ability of the organism to adaptively defend itself against
toxic foreign compounds. Since the discovery of CYP in-
duction by the barbiturate phenobarbital (PB) 
 

 
40 years
ago (4), this molecule has served as a prototype for a large
group of structurally and functionally diverse compounds
that induce the expression of CYP2B genes (5), whereas
the glucocorticoid dexamethasone and the antibiotic rifampi-
cin represent drugs that increase CYP3A levels in humans
(6). There is, however, considerable overlap between the
different inducers and the patterns of genes that they in-
duce. The induction of drug-metabolizing CYP has impor-
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tant clinical consequences: 
 
1
 
) it affects the efficiency of
drug treatment; 
 
2
 
) it may cause drug-drug interactions; and
 
3
 
) it can influence endogenous regulatory pathways.
Numerous studies have established that members of the
nuclear receptor superfamily of transcription factors are
essential in mediating this drug response (reviewed in 7).
Specifically, the constitutive androstane receptor (CAR),
the pregnane X receptor (PXR), and the chicken xenobi-
otic receptor have been assigned key roles in the induc-
tion of CYP2B, CYP2C, CYP3A, and CYP2H1 genes in hu-
man, mouse, and chicken (8–13).
At the same time, CYP-catalyzed reactions are pivotal in
the regulation of cholesterol balance and the synthesis
and metabolism of steroids and vitamin D. Thus, although
cholesterol homeostasis relies on multiple checkpoints,
cholesterol 7
 

 
-hydroxylase (CYP7A1) is the first and rate-
limiting enzyme in the conversion of cholesterol to bile
acids (14, 15). Two nuclear receptors, the farnesoid X re-
ceptor (FXR) and the liver X receptor (LXR), are impor-
tant regulators of CYP7A1. Thus, in the mouse, Cyp7a1 is
induced by oxysterols via LXR (16, 17). The same gene can
be repressed by bile acids via FXR. Here, FXR activates the
small heterodimer partner, which in turn inhibits consti-
tutive transcriptional activation by the liver receptor ho-
molog-1 transcription factor on the CYP7A1 promoter
(18, 19).
A large body of in vivo and in vitro data support the
concept that the molecular mechanisms of hepatic drug
induction are linked to endogenous regulatory pathways:
observations made in epileptic patients treated with anti-
convulsants and in rats treated with PB have revealed in-
creased plasma cholesterol and lipoprotein levels (20–25).
Moreover, a study of a 264 bp phenobarbital-responsive
enhancer unit (PBRU) from the chicken CYP2H1 gene
demonstrated that a DR4-type nuclear receptor response
element (direct hexamer repeat separated by four nucle-
otides) contained within this PBRU was essential for
conferring drug induction and that in the LMH chicken
hepatoma cell line oxysterols can inhibit the PB induction
mediated by this 264 bp PBRU through competitive bind-
ing of LXR to the DR4 element (26).
To study the link between LXR, cholesterol homeosta-
sis, and drug induction in vivo, we designed experiments
in mice lacking one or both LXR isoforms. Wild-type,
LXR
 

 
-, LXR
 

 
-, and LXR
 

 
/
 

 
-deficient mice were kept on
standard laboratory chow or a 2% enriched cholesterol diet
for 1 week and were given either vehicle (0.9% saline solu-
tion) or PB intraperitoneally. Subsequently, levels of Cyp7a1,
Cyp2b10, and Cyp3a11, two murine drug-metabolizing en-
zymes, as well as cholesterol and bile acid transporters
were quantified by real-time PCR. Cholesterol and triglyc-
eride (TG) levels also were determined from the animals’
livers.
In this report, we provide evidence for important cross-
talk between xenobiotic- and oxysterol-sensing nuclear re-
ceptors in the regulation of enzymes involved in drug and
cholesterol metabolism. Our data reveal differential regu-
latory patterns for Cyp2b10 and Cyp3a11 dependent on
the expression of LXR isoforms and on challenge of cho-
lesterol metabolism by excess dietary cholesterol. Our re-
sults suggest that in the mouse, liver cholesterol status sig-
nificantly alters the pattern of expression of Cyp3a11,
whereas the absence of LXR leads to an increase in PB-
mediated activation of Cyp2b10. Finally, we demonstrate
that under certain conditions, PB treatment not only af-
fects drug-metabolizing enzymes but also influences he-
patic cholesterol levels.
MATERIALS AND METHODS
 
Reagents
 
22(
 
R
 
)-Hydroxycholesterol, 22(
 
S
 
)-hydroxycholesterol, 25-hydroxy-
cholesterol, and pregnenolone 16
 

 
-carbonitrile (PCN) were pur-
chased from Sigma (distributed by Fluka AG). 24(
 
S
 
),25-Epoxy-
cholesterol was a kind gift from Thomas A. Spencer (Department
of Chemistry, Dartmouth College, Hanover, NH). 27-Hydroxy-
cholesterol was obtained from Steraloids (Newport, RI).
 
Plasmids
 
The coding regions of mouse CAR and mouse LXR
 

 
 were am-
plified from mouse cDNA, followed by subcloning into the pSG5
expression vector (Stratagene, Basel, Switzerland). The expres-
sion vector for mouse PXR, pSG5-mPXR, was kindly provided
by Steven A. Kliewer (University of Texas Southwestern Medical
Center, Dallas, TX).
The pcDNA3 expression vector was obtained from Invitrogen
AG (Basel, Switzerland). The pcDNA3/VP16 construct was pro-
vided by Dieter Kressler (Biozentrum, University of Basel, Swit-
zerland). Vp16/mPXR was generated by PCR amplification of
the mouse PXR from pSG5-mPXR and by insertion into the 
 
Xba
 
I-
digested pcDNA3/VP16 vector; the primers harboring 
 
Xba
 
I re-
striction sites were chosen as follows: forward primer, 5
 

 
-GCT-
CTAGAAGCGGTAGCGGTAGACCTGAGGAGAGCTGGAGCC-3
 

 
;
reverse primer, 5
 

 
-GCTCTAGATCAGCCATCTGTGCTGCTAAA-
TAAC-3
 

 
. Vp16/mLXR
 

 
 was generated by amplification of the
mouse LXR from pSG5-mLXR
 

 
 and by insertion into the di-
gested 
 
Eco
 
RI pcDNA3/VP16 vector. The primers harboring 
 
Eco
 
RI
restriction sites were chosen as follows: forward primer, 5
 

 
-CTG-
AATTCAGTGGTAGCGGTTCCTTGTGGCTG-3
 

 
, reverse primer
5
 

 
-CGGAATTCTCACTCGTGGACATCCCAGATCTC-3
 

 
. The pSV-
 

 
Gal expression vector for 
 

 
-galactosidase used for the normal-
ization of transfection efficiencies was obtained from Promega
(Promega Corp., Catalys AG, Wallisellen, Switzerland).
The pGL3-basic plasmid containing 13 kb of human CYP3A4
5
 

 
 flanking region was a gift from Christopher Liddle (University
of Sidney at Westmead Hospital, Westmead, Australia). The xe-
nobiotic-responsive enhancer module (XREM; bases 
 

 
7,836 to
 

 
7,206) fragments were generated by PCR using primers spe-
cific to the sequence but tagged with a restriction endonuclease
site to permit cloning into the (
 

 
362/
 

 
53)pGL3-basic luciferase
reporter gene vector. Upstream primer 5
 

 
-ATGGTACCTCTAGA-
GAGATGGTTCATTCCT-3
 

 
 was used in combination with 5
 

 
-
CATAGATCTTGAAACATGTTTCTTTCCTTGT-3
 

 
 downstream
primer to generate the XREM.
The luciferase reporter plasmid containing two repeats of the
mouse Cyp7a1 LXR response element (27), (DR4)
 
2
 
tkluc, was pro-
duced using the oligonucleotides 5
 

 
-CTCTGGTCACCCAAGT-
TCAAGTTTCTGGTCACCCAAGTTCAAGTTC-3
 

 
 and 5
 

 
-TCGA-
GAACTTGAACTTGGGTGACCAGAAACTTGAACTTGGGTGA-
CCAGAGGTAC-3
 

 
 synthesized by Microsynth (Balgach, Switzer-
land). The double-stranded oligonucleotide was digested with
 
Kpn
 
I/
 
Xho
 
I and ligated into the pGL3tk luciferase. The pGL3tk
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luciferase reporter gene vector was constructed by excising the
thymidine kinase promoter from the pBLCAT5 reporter vector (28)
with 
 
Bam
 
HI and 
 
Bgl
 
II and inserting it into the 
 
Bgl
 
II site of the
pGL3-basic promoterless reporter vector (Promega Corp., Catalys
AG). All PCR products were verified by sequencing.
 
Animals
 
LXR
 

 
-, LXR
 

 
-, and LXR
 

 
/
 

 
-deficient mice were generated as
described previously (29, 30). All LXR knockout mice used in
our study were between 12 and 16 weeks old and had a similar
mixed genetic background based on 129/Sv and C57BL/6 strains.
Mice with pure 129/Sv background were backcrossed into C57BL/6
mice for seven generations (29, 30). LXR-deficient mice and
C57BL/6 wild-type control mice were bred by Taconic M&B. Af-
ter delivery, all mice were allowed to adjust for 2 weeks and were
housed with a regular 12 h light/12 h dark cycle. Mice were fed
ad libitum either a low-fat standard rodent chow diet (R36; Lac-
tamin AB, Vadstena, Sweden) or diet supplemented with 2% (w/w)
cholesterol for 1 week. Female mice (n 
 

 
 5–8) were kept on stan-
dard or cholesterol-supplemented chow and were injected one
time intraperitoneally with vehicle alone (saline) or PB (100
mg/kg). After 16 h, animals were killed and livers excised and
maintained in RNAlater (Ambion, Inc., Austin, TX) according to
the manufacturer’s protocol. Liver tissue samples were solubi-
lized in 1 ml of TRIzol™ reagent (Invitrogen AG, Basel, Switzer-
land) and homogenized for 5 s in FastRNA tubes using a Fast-
Prep FP120 homogenizer from Qbiogene (Carlsbad, CA), and
total RNA was extracted according to the TRIzol protocol. Ex-
periments were approved by the local ethics committee for ani-
mal experiments.
 
Chemical analysis of serum and tissue
 
Blood was drawn by cardiac puncture under light methoxyflu-
orane anesthesia before tissues were collected for further analy-
ses. Total cholesterol and TGs were determined with a Monarch
automated analyzer (ILS Laboratories Scandinavia AB, Sollen-
tuna, Sweden). Lipids were extracted according to Folch, Lees,
and Sloane Stanley (31). Total cholesterol and TG were analyzed
using commercially available kits (Roche Molecular Biochemi-
cals, Indianapolis, IN).
 
Taqman analysis
 
One microgram of mouse liver RNA was reverse-transcribed
with the Moloney murine leukemia virus reverse transcriptase
(Promega Corp., Catalys AG) using oligo-(dT)15 N primers. PCR
was performed with qPCR™ Mastermix Plus (Eurogentec GmbH,
Köln, Germany). Transcript levels were quantified with an ABI
Prism 7700 sequence detection system (PE Applied Biosystems)
according to the manufacturer’s protocol. Briefly, relative tran-
scripts levels in induced livers and untreated controls were deter-
mined using the comparative Ct (cycle threshold) method.
Multidrug resistance-associated protein 3 (MRP3) amplification
products were detected using the Master Mix SYBR
 
®
 
 Green 1 as-
say (Eurogentec GmbH), and the primers were optimized as fol-
lows: forward primer, 5
 

 
-GGCCTTTCTGTGTCCTATGCCTTA-3
 

 
(500 nM); reverse primer, 5
 

 
-CCTTGACTCTCTCCACAGCTA-
TGA-3
 

 
 (500 nM). Levels of GAPDH were used for normaliza-
tion. All other primers and probes were chosen as indicated in
 
Table 1
 
.
 
Transcriptional activation assays
 
Transactivation assays were carried out in CV-1 green monkey
kidney cells as described previously (32). Briefly, cells were ex-
panded for 3 days in DMEM-F12 without phenol red supple-
mented with 10% charcoal-treated FBS. Subsequently, cells were
plated onto 96-well dishes at a density of 25,000 cells/well and
grown overnight. For transfection, cells were maintained in Opti-
MemI (Invitrogen). Transfection mixes contained 20 ng of re-
ceptor expression vector, 8 ng of reporter vector, 60 ng of pSV-
 

 
Gal, and carrier plasmid to a total of 100 ng of DNA per well.
Cells were transiently transfected using the LipofectAMINE re-
agent (Invitrogen) according to the manufacturer’s protocol. Af-
ter 24 h of incubation, cells were exposed to drugs or vehicle for
an additional 24 h. Transfections with vectors expressing consti-
tutively active nuclear receptors were carried out for 48 h, and
then cells were lysed. Cell extracts were prepared using 100 
 

 
l of
passive lysis buffer (Promega Corp., Catalys AG). The superna-
tants were assayed for luciferase activities using the Luciferase
Assay kit (Promega Corp., Catalys AG) and a Wallac 1420 Multila-
bel Counter. 
 

 
-Galactosidase activities were measured as described
previously (13). Luciferase levels were then normalized against
 
TABLE 1. Taqman primer and probe sequences
 
Target Gene  Primer/Probe Sequence Concentration
 
nM
 
Cyp2b10 Forward: 5
 

 
-CAATGTTTAGTGGAGGAACTGCG-3
 

 
900
Reverse: 5
 

 
-CACTGGAAGAGGAACGTGGG-3
 

 
900
Probe: 5
 

 
-FAM-CCCAGGGAGCCCCCCTGGA-TAMRA-3
 

 
300
Cyp3a11 Forward: 5
 

 
-AGAACTTCTCCTTCCAGCCTTGTA-3
 

 
900
Reverse: 5
 

 
-GAGGGAGACTCATGCTCCAGTTA-3
 

 
900
Probe: 5
 

 
-FAM-CTAAAGGTTGTGCCACGGGATGCAGT-TAMRA-3
 

 
300
Cyp7a1 Forward: 5
 

 
-ACACCAAGTGTCCCCCTCTAGA-3
 

 
900
Reverse: 5
 

 
-CTCAATATCATTTAGTGGTGGCAAA-3
 

 
900
Probe: 5
 

 
-FAM-CAGTCCCGGGCAGGCTTGGG-TAMRA-3
 

 
300
ABCA1 Forward: 5
 

 
-GGACATGCACAAGGTCCTGA-3
 

 
900
Reverse: 5
 

 
-CAGAAAATCCTGGAGCTTCAAA-3
 

 
900
Probe: 5
 

 
-FAM-AATGTTACGGCAGATCAAGCATCCCAAC-TAMRA-3
 

 
300
ABCG5 Forward: 5
 

 
-TCAGGACCCCAAGGTTCATGAT-3
 

 
900
Reverse: 5
 

 
-AGGCTGGTGGATGGTGACAAT-3
 

 
300
Probe: 5
 

 
-FAM-CCACAGGACTGGACTGCATGACTGCA-TAMRA-3 50
ABCG8 Forward: 5-GACAGCTTCACAGCCCACAA-3 900
Reverse: 5-GCCTGAAGATGTCAGAGCGA-3 300
Probe: 5-FAM-CTGGTGCTCATCTCCCTCCACCAG-TAMRA-3 50
GAPDH Forward: 5-CCAGAACATCATCCCTGCATC-3 900
Reverse: 5-GGTCCTCAGTGTAGCCCAAGAT-3 900
Probe: 5-FAM-CCGCCTGGAGAAACCTGCCAAGTATG-TAMRA-3 300
FAM, 6-carboxyfluorescein; TAMRA, 6-carboxy-tetramethyl-rhodamine.
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-galactosidase values to compensate for the variation in trans-
fection efficiencies and against untreated control cells to obtain
relative luciferase activities.
RESULTS
LXR deficiency and its effect on the basal expression of 
drug-metabolizing enzymes
To investigate the effects of LXR, LXR, or LXR/
deficiency on the expression of Cyp2b10 and Cyp3a11, we
measured the mRNA levels of these genes in the livers of
mice receiving normal diet and treated with vehicle. As il-
lustrated in Fig. 1A, Cyp2b10 and Cyp3a11 show different
regulation patterns. Although the absence of one or both
LXR isoforms did not significantly affect levels of Cyp2b10
transcript, the basal level of Cyp3a11 mRNA was signifi-
cantly increased in LXR/-deficient mice. Hepatic cho-
lesterol levels were measured in mice on normal diet (Fig.
1B), and in accordance with previously published data
(30), total liver cholesterol was found to be increased sig-
nificantly in LXR/-deficient mice.
Effect of dietary cholesterol on the expression of 
Cyp3a11 and Cyp2b10
Mice with different LXR genotypes were fed with a 2%
cholesterol diet for 1 week, after which the expression of
Cyp2b10 and Cyp3a11 (Fig. 2) was evaluated. The effi-
ciency of the diet in activating LXR was tested by measur-
ing Cyp7a1 mRNA levels under both normal and high-
cholesterol dietary conditions (Fig. 2C). We observed a
significant increase in Cyp7a1 expression in wild-type
animals when challenged with the 2% cholesterol diet,
whereas no significant effect was observed among the
other genotypes. Interestingly, 2% cholesterol feeding af-
fected Cyp2b10 and Cyp3a11 expression in a genotype-
dependent manner. Expression of Cyp3a11 and Cyp2b10
mRNA is shown in Fig. 2A, B, respectively. In wild-type an-
imals and LXR-deficient mice, dietary cholesterol did
not significantly alter the expression of either gene. In
LXR- and LXR/-deficient mice, however, mRNA lev-
els of Cyp3a11 were increased significantly in response to
cholesterol; Cyp2b10 expression levels followed the same
profile, but the changes were not statistically significant.
This pattern of induction correlates with the liver choles-
terol content profiles (Fig. 2D), in which cholesterol is
strongly increased in LXR- and LXR/-deficient mice.
These results suggest that the influence of cholesterol
feeding on Cyp2b10 and Cyp3a11 expression occurs when
LXR is absent and liver cholesterol content is high, par-
tially as a result of the lack of Cyp7a1 induction by LXR.
Cholesterol feeding reduces PB-mediated increase of 
Cyp2b10 independently of LXR genotype
As shown previously in vivo (33), PB massively induces
Cyp2b10 (140-fold) in wild-type mice under standard di-
etary conditions (Fig. 3A). In mice lacking LXR or both
LXR isoforms, this strong PB-mediated induction was in-
creased further (Fig. 3A), suggesting that the absence of
LXR positively influences the capacity of Cyp2b10 to be
induced by PB. When wild-type or LXR-deficient mice are
treated with PB while fed a 2% cholesterol diet, decreased
inducibility by PB was observed, irrespective of LXR geno-
type (Fig. 3A). This repression of PB induction by dietary
cholesterol thus seems to be LXR-independent, which im-
plies that the hepatic cholesterol status affects the regula-
tion of the drug-metabolizing enzyme Cyp2b10.
Effect of cholesterol feeding on PB-mediated induction 
of Cyp3a11
To study the influence of dietary cholesterol on the PB-
mediated increase of Cyp3a11, mRNA levels were deter-
mined in mice fed standard chow or a 2% cholesterol diet
and treated with either vehicle or PB (Fig. 3B). In mice of
all LXR genotypes, PB induced Cyp3a11 expression. How-
ever, this PB-mediated increase was smaller in LXR/
-deficient mice, whereas the basal level of Cyp3a11 ex-
pression was higher than in the wild type (Fig. 1A). In con-
trast to Cyp2b10, cholesterol feeding did not significantly
reduce PB-mediated induction of Cyp3a11 mRNA in any of
the mouse genotypes. PB induction of Cyp3a11 is thus ap-
parently independent of dietary cholesterol content.
PB treatment affects hepatic TG and cholesterol levels
To evaluate the effect of PB on cholesterol homeostasis
and lipogenesis, hepatic cholesterol and TG levels were
Fig. 1. Regulation of cytochrome P450 3a11 (Cyp3a11) and
Cyp2b10 expression in liver X receptor (LXR)-deficient (/)
mice. A: Wild-type (WT), LXR-, LXR-, and LXR/-deficient
mice (n  5–8) were kept on standard laboratory chow and given
vehicle intraperitoneally (saline) for 16 h. Hepatic Cyp2b10 and
Cyp3a11 levels were determined by real-time PCR. Gene levels are
expressed relative to the wild-type control. Error bars represent SD.
B: Total cholesterol levels were determined in the livers of wild-
type, LXR-, LXR-, and LXR/-deficient mice. Error bars repre-
sent SEM. * P 	 0.05 determined by Student’s t-test.
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measured in mice fed standard laboratory chow or the 2%
cholesterol diet (Fig. 4). Compared with wild-type animals,
LXR/-deficient mice displayed significantly decreased
levels of hepatic TG (Fig. 4A) in the absence of drug treat-
ment, consistent with previous observations (30). When
mice were fed standard chow, PB treatment had no signif-
icant effect on hepatic TG. In contrast, PB significantly de-
creased hepatic TG levels in wild-type, LXR-deficient,
and LXR-deficient animals but not in LXR/-deficient
mice (Fig. 4B) on the 2% cholesterol diet. Furthermore,
hepatic cholesterol levels of LXR/-deficient mice were
increased significantly compared with the other genotypes
when mice were fed standard chow (Fig. 4C), in agree-
ment with previously published data (30). Most interest-
ingly, PB treatment was found to decrease hepatic choles-
terol levels in mice on the high-cholesterol diet, and this
Fig. 3. Effect of cholesterol feeding on phenobarbital (PB)-mediated increase of Cyp2b10 and Cyp3a11.
Wild-type (WT), LXR-, LXR-, and LXR/-deficient (/) mice (n  5–8), fed standard laboratory
chow or a 2% cholesterol-supplemented diet for 1 week, were administered either vehicle (saline) or PB
(100 mg/kg) for 16 h. Cyp2b10 (A) and Cyp3a11 (B) levels were quantified by real-time PCR. The PB-medi-
ated increase in gene expression is calculated for each genotype and feeding condition and expressed as fold
increase relative to that of the corresponding vehicle-treated control. Error bars represent SD. * P 	 0.02 de-
termined by Student’s t-test.
Fig. 2. Effect of 1 week of 2% cholesterol feeding on cholesterol 7-hydroxylase (Cyp7a1), Cyp2b10, and
Cyp3a11 expression in LXR-deficient (/) mice. Wild-type (WT), LXR-, LXR-, and LXR/-deficient
mice (n  5–8) were fed standard laboratory chow or a diet supplemented with 2% cholesterol for 1 week.
Real-time PCR analysis was performed with probes specific for Cyp2b10 (A), Cyp3a11 (B), or Cyp7a1 (C).
Hepatic gene levels are expressed relative to those in wild-type vehicle-treated control animals on a standard
diet. Error bars represent SD. D: Total cholesterol levels were determined in the livers of wild-type, LXR-,
LXR-, and LXR/-deficient mice. Error bars represent SEM. * P 	 0.001 determined by Student’s t-test.
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effect was independent of their LXR genotype (Fig. 4D).
In mice kept on the normal diet, PB did not further de-
crease hepatic cholesterol levels, with the exception of
LXR/-deficient mice (Fig. 4D), which exhibited in-
creased cholesterol levels already under normal dietary
conditions (Fig. 4C).
The occurrence of this effect in LXR/-deficient mice
suggests that the capacity of PB to decrease hepatic cho-
lesterol levels is independent of LXR. Interestingly, the ef-
fect of PB occurs only when hepatic cholesterol and TG
levels are increased.
PB affects hepatic cholesterol levels by acting on Cyp7a1 
and MRP3 expression
To gain insight into the pathways by which PB modifies
hepatic cholesterol levels, Cyp7a1 mRNA levels were quan-
tified by Taqman analysis (Fig. 5A). In addition to the in-
crease observed in wild-type vehicle-treated mice upon
cholesterol feeding, a PB-mediated increase in Cyp7a1 ex-
pression was measured in LXR/-deficient mice under
both feeding conditions. PB treatment did not lead to sig-
nificant changes in Cyp7a1 expression in the other geno-
types (data not shown), suggesting that this effect occurs
predominantly in the total absence of LXR.
To examine the molecular details underlying the activa-
tion of Cyp7a1, we cloned a tandem repeat of a previously
identified LXR response element from the Cyp7a1 gene
Fig. 4. PB treatment affects triglyceride (TG) and cholesterol levels. Wild-type (WT), LXR-, LXR-, and
LXR/-deficient (/) mice (n  5–8), fed standard laboratory chow or a 2% cholesterol-supplemented
diet for 1 week, were administered either vehicle (saline) or PB (100 mg/kg) for 16 h. TG contents in livers
from animals fed standard chow (A) or 2% cholesterol (B) as well as total cholesterol contents in animals fed
standard chow (C) or 2% cholesterol (D) and treated with vehicle or PB were determined. Error bars repre-
sent SEM. * P 	 0.05 determined by Student’s t-test.
(27) into a luciferase reporter vector under the control of
the thymidine kinase promoter. This reporter construct,
(DR4)2tkluc, was then used in transcriptional activation
assays in CV-1 cells (Fig. 5B, C). As expected, reporter activ-
ity was increased when cells were cotransfected with a
VP16mLXR construct expressing a constitutively active
derivative of the mouse LXR isoform (Fig. 5B). It is well
established that PB mediates the activation of drug-metab-
olizing CYP3A and CYP2B enzymes via PXR and CAR (5).
For this reason, we tested whether these two nuclear re-
ceptors interact with the known regulatory sequence in
the mouse Cyp7a1 gene in vitro. Interestingly, (DR4)2tkluc
reporter activity was strongly increased when cells were
cotransfected with a plasmid expressing a constitutively
active mouse PXR-VP16 fusion protein (Fig. 5B).
When cells were cotransfected with an expression vec-
tor for mouse CAR (Fig. 5C), a 3-fold increase of basal ac-
tivation was observed. The activity of mouse CAR can be
modulated by androstanol, an inverse agonist, and by the
inducer compound TCPOBOP [1,4-bis(3,5-dichloropyri-
dyloxy) benzene], as has been reported (34). Using these
compounds, we could modulate the expression of the
(DR4)2tkluc reporter (Fig. 5C) to a comparable extent
as reported for bona fide CAR target genes. These data
implicate PXR and CAR in the regulation of mouse
Cyp7a1, particularly in the absence of LXRs, and suggest
that the cholesterol-lowering effect observed in the pres-
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ence of PB (Fig. 4C, D) is, at least in part, mediated by
PXR or CAR and may be the result of increased choles-
terol catabolism. Because PB did not lead to a significant
upregulation of Cyp7a1 when wild-type mice received a
standard diet (Fig. 5A) and when LXR- or LXR-defi-
cient mice were fed cholesterol (data not shown), PB may,
in these cases, decrease hepatic cholesterol levels by
increasing the export of cholesterol and/or bile acids.
Therefore, we quantified the expression levels of several
genes implicated in cholesterol and bile acid transport in
mouse liver. None of the cholesterol transporters ABCA1
(35), ABCG1 (36), or ABCG5/ABCG8 (37) was induced
by PB, either in LXR/-deficient mice under standard
dietary conditions or in any of the four mouse genotypes
when challenged with cholesterol feeding; therefore, the
regulation pattern of these transporters cannot explain
the effect of PB observed on liver cholesterol (data not
shown). Interestingly, however, MRP3 expression was in-
creased in all genotypes by PB when mice were fed choles-
terol (Fig. 5D), suggesting that bile salt export from the
liver is increased in those animals in which liver choles-
terol was increased. PB treatment also increased MRP3 ex-
pression in wild-type mouse liver, confirming previous ob-
servations (38).
Cholesterol derivatives are activators of mouse PXR
To assess the potential of cholesterol and several of its
derivatives to activate mouse PXR, transcriptional activa-
tion assays were performed in CV-1 cells (Fig. 6). PCN, a
known potent activator of murine PXR used as a positive
control, led to 18-fold activation of the reporter gene ac-
tivity over vehicle-treated cells. In addition, hydroxylated
derivatives of cholesterol, like the potent LXR agonist
24(S),25-epoxycholesterol, also could activate PXR, con-
firming previous observations in mouse hepatocytes (39).
22(R)-Hydroxycholesterol displayed only weak activation
of PXR, whereas 22(S)-hydroxycholesterol was inactive. In-
terestingly, the 25- and 27-hydroxylated derivatives of cho-
lesterol proved to be good mouse PXR activators in vitro,
suggesting that fluctuation in the hepatic concentration
of these substances could affect PXR target gene regula-
tion.
DISCUSSION
In this report, we describe the influence of LXR and/
or LXR deficiency and the effect of cholesterol feeding
on the expression and PB-mediated induction of two mu-
rine drug-metabolizing enzymes, Cyp2b10 and Cyp3a11.
In addition, we describe the consequences of a short-term
PB treatment on hepatic cholesterol and TG content in
mouse livers.
Our data clearly show that LXR deficiency differentially
affects not only the basal expression levels of Cyp2b10 and
Cyp3a11 but also the capacity of these genes to be induced
by PB. Upon exposure to dietary cholesterol, Cyp2b10 and
Cyp3a11 exhibited a gene-specific response. Although no
significant effect of LXR deficiency was observed on the
Fig. 5. PB treatment affects the hepatic expression of Cyp7a1 and
multidrug resistance-associated protein 3 (MRP3). A: Wild-type and
LXR/-deficient mice (n  5–8), fed standard laboratory chow or
a 2% cholesterol-supplemented diet for 1 week, were administered
either vehicle (saline) or PB (100 mg/kg) for 16 h. Hepatic Cyp7a1
expression was determined by real-time PCR. Error bars represent
SD. * P 	 0.05 determined by Student’s t-test. B: A luciferase re-
porter vector containing two copies of the mouse Cyp7a1 LXR re-
sponse element, a direct-repeat separated by four nucleotides,
(DR4)2tkluc, was cotransfected in CV-1 cells together with expres-
sion vectors for VP16mLXR, VP16mPXR, or a control vector. Cell
extracts were analyzed for luciferase activities, which then were nor-
malized against -galactosidase activities. Luciferase activities rela-
tive to cells cotransfected with empty vector are shown. Values rep-
resent means of at least three independent experiments  SD. C:
(DR4)2tkluc was transfected in CV-1 cells with or without an expres-
sion vector for mouse constitutive androstane receptor (mCAR).
Cells were treated for 24 h with vehicle (0.1% DMSO), androstanol
(And; 5 M), and/or TCPOBOP [1,4-bis(3,5-dichloropyridyl-
oxy)benzene] (10 M). Cell extracts were analyzed as described
above. Absolute luciferase activities are shown. Values represent
means of at least three independent experiments  SD. D: MRP3
levels were determined by real-time PCR in the indicated mouse liv-
ers. Gene levels are expressed relative to the wild-type (WT) vehi-
cle-treated control. Error bars represent SD. * P 	 0.05 determined
by Student’s t-test.
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expression of Cyp2b10, Cyp3a11 was increased signifi-
cantly in mice lacking both LXR isoforms. This increase
may be either a direct consequence of the lack of LXR
and LXR (derepression of gene activation) or a response
to secondary events occurring in mouse liver linked to
LXR deficiency. Therefore, we determined hepatic choles-
terol levels and found them to be significantly higher in
LXR/-deficient mice compared with wild-type animals.
Cyp3a11 expression was increased in mice fed cholesterol
and displaying higher hepatic cholesterol content, whereas
no increase was seen in Cyp2b10 expression. Studies in
vitro have shown that CYP3A4 can metabolize cholesterol
to 4-hydroxycholesterol and that this metabolite is present
at relatively high concentrations in human plasma (40).
This metabolic conversion was shown to occur only for
CYP3A4 and not for CYP1A1, CYP2C9, or CYP2B6. Al-
though it is currently unknown whether the mouse ho-
molog Cyp3a11 metabolizes cholesterol like CYP3A4, a
possible interpretation of our findings is that cholesterol
could act as a likely substrate for Cyp3a11 and may in-
crease its own metabolism when present in the liver in
large amounts. Indeed, in wild-type mice, cholesterol feed-
ing leads to an activation of LXR and its target gene
Cyp7a1, which leads to an increase in cholesterol metabo-
lism, decreases cholesterol levels, and presumably does
not increase Cyp3a11. By contrast, in LXR-deficient mice,
cholesterol levels are not controlled by LXR and Cyp7a1;
therefore, they are excessive and may induce Cyp3a11.
As murine PXR is well known as a key regulator of
Cyp3a11 expression both in vitro and in vivo (41), we sus-
pect that the induction observed can be at least partially
attributable to the activation of this nuclear receptor. In
addition to cholesterol, the levels of several of its hydroxyl-
ated derivatives are increased in mice when one or both
LXRs are ablated or when mice are fed cholesterol (42).
Thus, it is known that 24(S),25-epoxycholesterol accumu-
lates in the liver after cholesterol feeding (43). Moreover,
wild-type mice and mice lacking LXR have been de-
scribed to have increased circulating levels of 27-hydroxy-
cholesterol when fed 2% cholesterol (29). Rats, when kept
on an atherogenic diet, show a considerable increase in
25-hydroxycholesterol in liver homogenates, whereas 27-
hydroxycholesterol levels remain unaffected (44). Based
on these observations, and considering the remarkable cor-
relation between hepatic cholesterol levels and Cyp3a11
expression, we evaluated the potential of several hydroxyl-
ated derivatives of cholesterol to activate mouse PXR in
cell culture. 24(S),25-Epoxycholesterol was a good activa-
tor of mouse PXR in our system, in accordance with previ-
ous observations in mouse hepatocytes (39). Interestingly,
25- and 27-hydroxycholesterol efficiently activated murine
PXR as well. These data suggest that in mice, not only bile
acid precursors (45) and bile acids (41) but also other en-
dogenous cholesterol derivatives can regulate Cyp3a11 ex-
pression via PXR.
Induction of Cyp2b10 and Cyp3a11 by PB was studied
in LXR-deficient and cholesterol-fed mice. Compared with
wild-type animals, LXR- or LXR/-deficient mice showed
significantly higher induction of Cyp2b10 mRNA levels,
suggesting that LXRs can repress PB-mediated activation
of Cyp2b10 in vivo in mice. Moreover, when mice were fed
cholesterol, the PB-mediated increase in expression was
reduced independently of the genotype, suggesting that
this dietary effect on induction is not LXR-dependent. For
Cyp3a11, the situation is probably different, because
whereas dietary cholesterol had no effect on PB induction
in wild-type and single-LXR-deficient mice, a significant
decrease of induction occurred in LXR/-deficient mice.
However, the reduced capacity of Cyp3a11 to respond to
PB may be a consequence of the high basal expression of
the gene in the absence of LXRs, preventing further re-
sponse. Moreover, when mice were fed cholesterol, no sig-
nificant difference was observed in the PB-mediated re-
sponse of Cyp3a11 compared with standard chow feeding,
in contrast to our observations with Cyp2b10.
In addition to the effect of PB on murine drug-metabo-
lizing enzymes, we were also interested in studying the ef-
fect of short-term PB treatment on hepatic TG and choles-
terol levels, especially given that cholesterol and several of
its derivatives can act as important signaling molecules.
Hepatic TG production is determined mainly by the fatty
acid synthesis rate, which is controlled to a large extent at
the transcriptional level by peroxisome proliferator-acti-
vated receptor , which stimulates fatty acid -oxidation
(46), and by sterol-regulatory element binding protein 1c
(SREBP-1c) (47), which controls fatty acid synthesis. In ad-
dition to cholesterol transport genes, LXR has been iden-
tified as an important regulator of SREBP-1c and de novo
lipogenesis (48). The TG-lowering effect of PB occurred
Fig. 6. 24(S),25-Epoxycholesterol, 25-hydroxycholesterol, and 27-
hydroxycholesterol activate mouse pregnane X receptor (mPXR)
in vitro in cell culture. A luciferase reporter construct containing
the human CYP3A xenobiotic-responsive enhancer module was
cotransfected in CV-1 cells with an expression vector for mouse
PXR. Cells were treated for 24 h as indicated with vehicle (0.1%
DMSO), pregnenolone 16-carbonitrile (PCN; 10 M), 24(S),25-
epoxycholesterol (24,25; 10 M), 22(R)-hydroxycholesterol (22R;
10 M), 22(S)-hydroxycholesterol (22S; 10 M), 25-hydroxycholes-
terol (25OH; 10 M), or 27-hydroxycholesterol (27OH; 10 M).
Cell extracts were analyzed as described above. Relative luciferase
activities were calculated over vehicle-treated cells. Values represent
means of at least three independent experiments  SD.
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only when wild-type, LXR-deficient, or LXR-deficient
mice were fed cholesterol and had increased TG before
PB treatment. Our data show that PB treatment signifi-
cantly decreases hepatic cholesterol levels, but only when
they are high. The main pathway for the elimination of
cholesterol is its conversion to bile acids, which is depen-
dent on Cyp7a1. In mice, positive regulation of Cyp7a1 is
mediated by LXR (17), whereas negative feedback is ex-
erted by bile acids via FXR and the small heterodimer
partner (19). Moreover, it has been shown that PCN treat-
ment represses Cyp7a1 expression in vivo in mice and that
this effect is PXR-dependent (49). Interestingly, we ob-
served that, in LXR/-deficient mice, PB acts as a posi-
tive regulator of Cyp7a1 under both dietary conditions,
thus potentially explaining the observed decrease in cho-
lesterol levels under these circumstances. A similar obser-
vation was made in earlier studies in rats, in which PB
treatment led to a decreased content of cholesterol in liver
microsomes in a strain that responded with increased Cyp7a1
activity (50). In addition, we showed in vitro that not only
PXR but also CAR can interact with the DR4 element
present in the 5 flanking region of the murine Cyp7a1,
providing a mechanism for this particular effect of PB. An
additional mechanism to reduce cholesterol levels by PB
could be the activation of MRP3 and the consequent in-
creased excretion of bile salts.
In conclusion, our data demonstrate that basal and PB-
induced expression of Cyp2b10 and Cyp3a11 is differen-
tially and specifically influenced by the absence of LXR as
well as the status of cholesterol in the liver. These observa-
tions suggest that cholesterol and its hydroxylated deriva-
tives are endogenous signaling molecules, normally serv-
ing as ligands to LXR, but under extraordinary conditions,
such as stringent diet or the absence of functional LXR,
they may also serve as ligands for other nuclear receptors
such as PXR or CAR and therefore affect the expression
of drug-metabolizing enzymes. Indeed, recent gene ex-
pression data in cholesterol-fed mice support the concept
that cholesterol or its products increase a number of PXR/
CAR target genes (A. Roth, R. Looser, and U. A. Meyer,
unpublished observation). The intricate nuclear receptor
signaling network allows a single gene to be a target for
several nuclear receptors, sensing different markers of en-
dogenous or exogenous origin. Our findings suggest that
processes that influence hepatic cholesterol levels, such as
defects in cholesterol biosynthesis pathways or hepatic ac-
cumulation of lipids, can ultimately alter drug metabo-
lism, affecting the efficiency of drug treatment.
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